0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-61.99%PremiumJan 17, 2025Expiry Date12.23Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.68Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viridian Therapeutics Stock Discussion
Will become the defacto drug for TED treatment and corner the market. Even helps to treat chronic TED. The results are truly impressive. The current market size for this disease treatment is about USD2bn
somehow lost on $NIO Inc (NIO.US)$ earlier but we can't stop won't stop 😂😭
2 MINUTES AGO, 4:01 PM EDT
VIA BUSINESSWIRE
📊⚡️📊
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Viridian Therapeutics (NASDAQ: VRDN) announced positive topline results from the THRIVE Phase 3 clinical trial of veligrotug (VRDN-001) in patients with active thyroid eye disease (TED). The trial met all primary and secondary endpoints, showing significant improvements in proptosis, diplopia, and clinic...
$Day One Biopharmaceuticals (DAWN.US)$ $Viridian Therapeutics (VRDN.US)$ $Bristol-Myers Squibb (BMY.US)$ $BioNTech (BNTX.US)$
FIRST SIGNED OF MORE UPTREND: $24.19
NEED IT TO BREAK OVER: $24.28
key indicator for MORE uptrend $24.47
confirmation uptrend - $24.65
mini breakout - $24.84. $Viridian Therapeutics (VRDN.US)$
No comment yet